Burlison opposes Pharmacists Fight Back Act in Oversight markup over PBM reimbursement rules
Embed this grade
Why this grade: Graded B-: core policy arguments rest on one verifiable state bill projection and stakeholder opposition claims that align with available context, but lack broader data or counter-evidence on net effects.
Why this lean: Frames PBMs positively as cost-savers via market mechanisms like Walmart and opposes government reimbursement mandates as cost drivers.
Disagree with this grade or political lean?
Tell us why. Your note is reprocessed through the same grading logic; if the output is still off the report is removed, and if it holds up it stays.
Topics in this report
Summary
During a House Oversight Committee markup, Rep. Eric Burlison spoke against the Pharmacists Fight Back Act (H.R. 6610). The bill would set pharmacy reimbursement at national average drug acquisition cost plus fees, require point-of-sale rebates, mandate full rebate pass-through, and prohibit PBM steering of patients to specific pharmacies. Burlison drew on his experience on a Missouri insurance board to defend PBMs' economies of scale and performance-based pay. He referenced a 2023 Louisiana HB 529 projection of $37 million added costs and opposition from FEHB plans including Government Employee Health Association and Mail Handlers Benefit Plan.
Editorial Assessment
The statement accurately describes bill provisions and draws on a documented Louisiana fiscal analysis for one claim. It omits counter-analyses showing potential savings from transparency rules or independent pharmacy impacts. Framing emphasizes PBM efficiency without addressing documented spread pricing or rebate retention practices. Viewers miss competing estimates from CBO or GAO on similar reforms and perspectives from pharmacists or patient advocates. As a single-member floor statement, sourcing is limited to the speaker's experience and one state example.
Key Moments
Louisiana HB 529 projected $37 million cost increase in first year from rate-setting
Referenced in 2023-2025 legislative testimony and PCMA materials on similar PBM reimbursement mandates.
FEHB plans including Government Employee Health Association and Mail Handlers Benefit Plan oppose the bill over mail-order and cost impacts
Bill targets FEHB; specific plan statements not independently confirmed in markup coverage, though industry groups have raised similar concerns.
Rebate point-of-sale and steering bans will drive up costs passed to customers
Opinion based on mechanism; bill sponsors argue transparency lowers net prices.
Notable Concerns
- Relies on single state bill projection without federal analogs or updated data